Market Overview

Markets are bifurcated this morning — the Dow is rising on defensive rotation while the Nasdaq is under pressure as Broadcom and CrowdStrike plunge on earnings disappointments. Oil approaching $98/barrel is renewing inflation concerns and pushing rate-cut expectations further out, benefiting healthcare and energy names while punishing high-multiple growth. The SpaceX IPO looming on June 12 and renewed US-Iran tensions over the Strait of Hormuz are adding volatility to an already complicated tape.

Top Movers

PLSE (+6.5%) — $26.61 → $30.00 (+12.7% upside) Thesis: CEO insider buy of 15,000 shares in May combined with the company’s strategic pivot toward atrial fibrillation (NANOPULSE-AF trial enrollment started) is giving the market confidence this isn’t just a science project anymore. RSI at 50 with neutral momentum suggests this is mid-move, not exhausted — the insider buy at lower levels provides a psychological floor. Levels: Exit at $30 (round number resistance / likely prior swing high). Support at $24.50 (pre-breakout consolidation zone).

M (+6.1%) — $23.13 → $25.50 (+10.2% upside) Thesis: Macy’s earnings reaction is driving this — the stock jumped 11% in May on recovery progress and today’s continuation suggests shorts are covering aggressively. RSI at 15.44 (deeply oversold on a longer timeframe) means this is a snapback rally from extremely washed-out levels, not a chase situation. The GLP-1-driven shift toward petite sizes could be a genuine structural tailwind for their inventory management story. Levels: Exit at $25.50 (May swing high area). Support at $21.80 (pre-earnings gap level).

HUM (+4.8%) — $343.30 → $365.00 (+6.3% upside) Thesis: Managed care is catching a bid on multiple tailwinds — aging demographics, CenterWell pharmacy expansion (new $83M Orlando facility processing 64K scripts/day), and sector rotation into defensives as oil-driven inflation fears hit. RSI at 79.3 is elevated and warrants caution, but the 11.2% weekly gain suggests institutional accumulation, not just a pop. Levels: Exit at $365 (round number / likely fib extension). Support at $310 (prior consolidation).

MDT (+4.1%) — $81.15 → $87.00 (+7.2% upside) Thesis: Stellar Q4 earnings drove a 5.7% move yesterday and follow-through today confirms the beat is being re-rated higher. Hugo RAS system FDA submission is a legitimate catalyst for surgical robotics narrative. Management called FY26 a “turning point” — and when Medtronic management gets bullish, it usually means the numbers are inflecting. RSI at 58.6 still has room before overbought. Levels: Exit at $87 (prior resistance / analyst target cluster). Support at $77.95 (yesterday’s open / gap fill level).

ELAN (+5.6%) — $25.94 → $28.50 (+9.9% upside) Thesis: Befrena launch (canine allergy biologic) makes Elanco the only pet health company with two USDA-approved monoclonal antibodies — this is a genuine competitive moat, not just another drug launch. The 9.8% move on the launch announcement is now getting follow-through as analysts likely begin revising revenue models upward. Levels: Exit at $28.50 (pre-decline resistance area). Support at $24.50 (20-day moving average area).

DHR (+3.8%) — $184.78 → $195.00 (+5.5% upside) Thesis: Danaher is bouncing from deeply oversold levels (RSI 1.72 — basically washed out completely) with the stock down 21.9% YTD. Cramer calling it “clearly overvalued” at these prices is a classic contrarian signal — when CNBC tells you to sell quality at 52-week lows, it’s usually time to nibble. Life sciences destocking cycle is ending. Levels: Exit at $195 (recent breakdown level / mean reversion target). Support at $179 (recent low).

TXG (+3.8%) — $33.38 → $38.00 (+13.8% upside) Thesis: Up 19.3% on the week — this is a legitimate breakout after the Atara spatial biology launch and beat-and-raise quarter. RSI at 39.8 is still in the lower half despite the rally, which means this was so beaten down (down 86% over 5 years) that even a 20% rip barely registers as overbought. CEO selling 30K shares is the yellow flag, though. Levels: Exit at $38 (prior resistance / fib level from 6mo range). Support at $28 (pre-breakout level).

FTRE (+4.8%) — $16.38 → $18.00 (+9.9% upside) Thesis: Fortrea’s turnaround is gaining credibility — shrinking losses, book-to-bill above 1.0 for three straight quarters, and reaffirmed guidance of $2.55-2.65B. The CRO space is recovering as biotech funding rebounds, and FTRE is a direct beneficiary. This is a “show me” story that’s starting to show. Levels: Exit at $18 (prior swing high). Support at $15 (recent consolidation floor).

ELV (+3.6%) — $405.18 → $430.00 (+6.1% upside) Thesis: Elevance is getting the same managed-care tailwind as Humana but with less overbought risk (RSI 65 vs. HUM’s 79). Evercore’s Tactical Outperform addition, avoided Medicare Advantage sanctions, and digital equity push expanding TAM all converge. Trading at a discount to peers with upside EPS expectations. Levels: Exit at $430 (round number / pre-decline level). Support at $390 (recent breakout zone).

TGTX (+3.5%) — $41.51 → $45.00 (+8.4% upside) Thesis: Positive Phase 1 data for subcutaneous Briumvi (MS treatment) converts a hospital-only IV drug into an at-home self-injection — that’s a multi-billion dollar TAM expansion for a mid-cap biotech. The 5-session losing streak broke with conviction on this data readout, and the “early buy signal” from IBD confirms technical momentum is turning. Levels: Exit at $45 (prior range high). Support at $38.50 (recent swing low).

Headlines to Watch

  • SpaceX IPO set for June 12 at ~$1.75T valuation — Largest IPO in history will force $22-27B in automatic index buying; expect liquidity to be pulled from other mega-caps as funds rebalance.
  • Oil approaching $98/barrel on Iran/Strait of Hormuz tensions — This is the single biggest macro risk right now; if oil crosses $100, expect a growth-to-value rotation to accelerate violently.
  • Vanguard VOO hits $1 trillion AUM — Passive flow dominance continues; the index inclusion trade (like SpaceX) matters more than ever when one ETF holds $1T.
  • Broadcom and CrowdStrike plunge on earnings — Semis and cybersecurity taking hits; watch for sympathy selling in AVGO-adjacent names and whether this signals peak AI spending expectations.
  • Medtronic seeks FDA clearance for Hugo RAS surgical robot — Direct shot at Intuitive Surgical’s da Vinci monopoly; MedTech rotation could have legs if approval timeline is favorable.
  • US-Iran ceasefire at risk per Trump comments — Geopolitical tail risk escalating; defense names and oil services (OIH up 51% YTD already) remain the hedge.
  • Oil services ETF (OIH) up 51% YTD — Already priced in a lot of good news; the “catch” is that Strait of Hormuz disruption is a double-edged sword for demand destruction vs. supply premium.

Claude’s Top Picks

MDT (+4.1% today, +7.4% week) — $81.15 → $87.00 (+7.2% upside) Valuation: At ~16x forward earnings for a MedTech giant with accelerating organic growth and Hugo RAS optionality, MDT is cheap relative to BSX (28x) and ISRG (55x) — PEG likely under 1.5. Upside: Earnings beat with raised guidance + FDA submission for Hugo creates a multi-quarter re-rating catalyst; this isn’t a one-day event. Risk: Tariff uncertainty on medical devices and TAVR competitive pressures could cap multiple expansion.

DHR (+3.8% today, +2.3% week) — $184.78 → $195.00 (+5.5% upside) Valuation: RSI at 1.72 is absurdly oversold; at 21x earnings with 5-7% organic growth resuming post-destocking, this is at the bottom of its historical valuation range after a 22% YTD drawdown. Upside: Life sciences destocking cycle is definitively ending; when consensus flips from “avoid” to “accumulate,” the re-rating is typically 15-20% in 2-3 months. Risk: Cramer flagging it as overvalued could mean more selling pressure near-term before the turn; patience required.

M (+6.1% today, +3.0% week) — $23.13 → $25.50 (+10.2% upside) Valuation: Trading at ~6x forward earnings with positive comps trajectory — absurdly cheap if the turnaround story has even modest credibility. Upside: RSI at 15.4 is one of the most oversold readings in the entire universe; mean reversion alone targets $25+ within two weeks. Risk: Retail is a graveyard; oil at $98 crimps consumer discretionary spending, and department stores remain structurally challenged.

TGTX (+3.5% today, +6.9% week) — $41.51 → $45.00 (+8.4% upside) Valuation: For a biotech with a $3B+ TAM expansion catalyst (subQ Briumvi), the current market cap appears reasonable relative to peers like SGEN was pre-acquisition. Upside: Subcutaneous formulation data de-risks the biggest bear case (hospital-only administration limits adoption); this is a legitimate franchise builder. Risk: Phase 1 safety data doesn’t guarantee Phase 3 success; binary biotech risk remains.

ELAN (+5.6% today, +8.2% week) — $25.94 → $28.50 (+9.9% upside) Valuation: At ~20x forward EV/EBITDA, it’s a premium to generic animal health peers but justified by the biologics portfolio moat (two USDA-approved MAbs, only company with this distinction). Upside: Befrena launch revenue won’t hit consensus models for 1-2 quarters; this is an under-modeled revenue stream that analysts will revise upward. Risk: Phased launch means revenue ramp is slow; execution risk on vet clinic adoption and competitive response from Zoetis.

Avoid

HUM (+4.8% today, RSI 79.3) — Already up 30.6% since last earnings and RSI is deeply overbought; the +11.2% weekly gain screams short-term exhaustion. Managed care is the right sector but this is the wrong entry point — wait for a pullback to $310-320.

IART (+4.4% today, RSI 72.9) — At 52-week highs with overbought RSI after a Citi upgrade; upgrades at highs are often the last catalyst before a consolidation. The “value” argument vs. MASI doesn’t hold when you’re chasing momentum at extended levels.

ORKA (+3.9% today) — Insider sold 105,000 shares worth $6.2M on May 31st. When insiders sell $6M at a clinical-stage biotech that’s up 126% YTD and 98% in 90 days, that’s a neon “take profits” sign. The psoriasis data is interesting but the risk/reward here heavily favors waiting.

WSB Sentiment Check

AVGO — WSB says: BULLISH (80% bullish) Claude says: PARTIALLY DISAGREE — AVGO just plunged on earnings today (it’s in the “Broadcom plunge” headline), meaning WSB is caught offsides. 80% bullish into an earnings miss is a classic bag-holder setup. The AI infrastructure story is intact long-term, but near-term this is a falling knife. Wait for the dust to settle at support before buying the dip.

MU — WSB says: MIXED (55% bullish) Claude says: AGREE — Mixed is the right call. Memory is cyclical and we’re mid-cycle; HBM demand for AI is real but ASP pressure from oversupply in conventional DRAM creates cross-currents. The 55% split accurately reflects the uncertainty. Not a high-conviction trade in either direction.

MRVL — WSB says: BEARISH (30% bullish) Claude says: PARTIALLY AGREE — Marvell has struggled to convince the market its custom silicon story justifies the multiple. Bearish sentiment at 30% after what was likely a disappointing quarter is understandable, but contrarian signals emerge below 25% bullish. This could become a buy if it finds support, but not yet.

SPCE — WSB says: BEARISH (30% bullish) Claude says: AGREE — With SpaceX IPO in 9 days at $1.75T, Virgin Galactic is about to become completely irrelevant as a “space” investment vehicle. Institutional money will flow from SPCE memes to actual SpaceX equity. This could be a death knell for SPCE as an investable stock. Avoid completely.

MSFT — WSB says: MIXED (55% bullish) Claude says: PARTIALLY DISAGREE — MSFT should be more bullish than 55%. It’s the best-positioned mega-cap for AI monetization (Copilot, Azure), and if the Nasdaq selloff today creates a pullback, it’s likely a gift. The SpaceX IPO rebalancing could temporarily pressure mega-caps, but that’s a buying opportunity, not a reason to be mixed.

Earnings Scorecard

M — BEAT (implied) | Stock: +6.1% | Reported: Recent (exact day unclear) The +6.1% reaction on top of an 11% May rally suggests the beat was meaningful — likely on both comps and margin improvement. With RSI at 15.4, the stock was so washed out that any positive surprise was going to trigger aggressive short covering. This is a buy-the-dip on any pullback to $21.50-22; the turnaround narrative has legs for another 10-15%.

MDT — BEAT (confirmed “stellar Q4”) | Stock: +4.1% (today’s continuation after +5.7% yesterday) | Reported: Wednesday After Close The two-day reaction of nearly 10% total is justified — management called FY26 a turning point, raised FY27 growth targets, and submitted Hugo RAS for FDA clearance simultaneously. This is a buy-the-breakout, not sell-the-rip. Medtronic doesn’t rally 10% in two days without fundamental conviction from long-only institutions re-underwriting the name.